S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/
Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/